Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Prog Retin Eye Res. 2021 Mar 26;85:100967. doi: 10.1016/j.preteyeres.2021.100967

Figure 12.

Figure 12.

TSG-6 as a biomarker predictive of the in vivo anti-inflammatory potency of MSCs.

For identification of a biomarker that predicts the clinical efficacy of MSCs, the level of myeloperoxidase (MPO), a semi-quantitative measure of activated neutrophils, was measured in the cornea in BALB/c mice 3 days after infliction of sterile corneal injury and IV administration of human BM MSCs. Then, the correlation between the efficacy of MSCs in reducing MPO levels in the cornea and the expression by RT-PCR of genes previously linked to the therapeutic benefits of MSCs was evaluated.

Among the analyzed genes, there was a highly-significant correlation between TSG6 transcript levels in MSCs (with and without TNF-α stimulation) and the efficacy of the cells in reducing corneal MPO levels.

Originally published in Proceedings of the National Academy of Sciences of the United States of America. Lee et al., 2014. TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc. Natl. Acad. Sci. U. S. A. 111, 16766–16771.